Skip to Content

Iressa Approval History

FDA Approved: Yes (First approved May 5, 2003)
Brand name: Iressa
Generic name: gefitinib
Dosage form: Tablets
Company: AstraZeneca
Treatment for: Non-Small Cell Lung Cancer

Iressa (gefitinib) is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

Development History and FDA Approval Process for Iressa

DateArticle
Jul 13, 2015Approval FDA Approves Iressa (gefitinib) for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
May  5, 2003Approval Astrazeneca Receives FDA Approval for New Cancer Drug Iressa (gefitinib, ZD1839)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide